IGI Logo

India holds more WHO-certified pharmaceutical manufacturing plants than any other country on earth. For three decades, the model has been consistent science invented in the West, scaled and delivered by India.

As per Vallum Capital's global research, the global genomics revolution now reshaping drug markets worldwide is not disrupting that model. It is setting up its next chapter. The same $300 billion patent expiry wave forcing Big Pharma into the most aggressive acquisition cycle in a decade is the identical event that has historically handed Indian manufacturers their largest growth windows. This time, the medicines expiring are not small molecules. They are biologics, gene therapies, and precision oncology drugs and India, with its Biopharma Shakti scheme, its Genome India Project mapping 10,000 genomes across 99 ethnic groups, and a domestic genomics market growing at over 16% annually, is actively building toward this moment

As per Vallum Capital's global macro research desk - July 2026: Genomics. (Data as on 24-07-2026)

That is the Indian chapter. Here is the global one.

The Rate Mechanism

The Global Genomic Revolution ETF is, structurally, a long-duration asset. Nearly 80% of its portfolio sits in small- and mid-cap companies whose value lies years in the future pre-profitable businesses whose distant earnings mathematics punishes most harshly when rates are high. The 2022–2024 collapse was not a science failure. It was a rates trade. When the US Federal Reserve cut rates three times in late 2025, those future cash flows were repriced upward almost immediately. The same mechanism that destroyed this fund in 2022 is now rebuilding it. Duration cuts both ways.

The Patent Cliff Forcing Big Pharma's Hand

An estimated $300 billion in branded drug revenues face patent expiry by 2030. Merck's flagship cancer drug alone $31.7 billion in 2025 sales begins losing exclusivity in 2028. Internal pipelines cannot replace that volume. Acquisition is the only answer, on a hard deadline. Biopharma M&A reached $106 billion across 201 deals in just the first half of 2026, on pace for the strongest full year since pre-pandemic. Premiums returned to the 50–100% range for quality clinical assets. Every deal that closes reprices every comparable asset still trading publicly and this theme's small- and mid-cap universe sits directly in the crosshairs of that institutional bid.

The AI Multiplier

AI is compressing drug discovery timelines from a decade to under 18 months on the right platform. Across the genomics sector, companies are now using clinical genomic data to accelerate target identification at a scale no conventional research organisation could match with some platforms running over a million biological experiments weekly using machine learning. This is no longer pipeline narrative. It is commercial revenue showing up in quarterly results, redefining what the productivity ceiling of drug development actually looks like.

The Capital Flywheel

M&A does not just lift acquired companies it mechanically restarts the entire capital cycle. A 70% acquisition premium on one biotech sets a new price floor for every comparable private company, which makes IPO pricing credible again, which draws generalist capital back in, which funds the next clinical cohort, which creates the next M&A cycle. In the first half of 2026, biotech IPOs raised more capital than the entire sector managed across all of 2025 a year when only 11 companies went public globally. Venture capital deployed into biotech hit $38 billion in 2025, up 28% year-on-year. The machine has restarted.

Above views are of the author and not of the website kindly read disclaimer